Rexatilux
Authorised
This medicine is authorised for use in the European Union
ranibizumab
MedicineHumanAuthorised
Romanian is available via eTranslation, the European Commission's machine translation service.
Translate to Romanian | Important information about machine translation
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
Rexatilux is a medicine used to treat adults with certain sight problems caused by damage to the retina (the light-sensing layer at the back of the eye), and more specifically its central region, known as the macula. The macula provides the vision needed to see detail for everyday tasks such as driving, reading and recognising faces. In adults, Rexatilux is used to treat:
- ‘wet’ form of age-related macular degeneration (AMD). The wet form of AMD is caused by choroidal neovascularisation (abnormal growth of blood vessels beneath the retina, which may leak fluid and blood and cause swelling);
- macular oedema (swelling of the macula) caused by diabetes or by occlusion (blockage) of the veins behind the retina;
- proliferative diabetic retinopathy (growth of abnormal tiny blood vessels in the eye, associated with diabetes);
- other sight problems associated with choroidal neovascularisation.
Rexatilux contains the active substance ranibizumab and is a biological medicine. It is a ‘biosimilar medicine’; this means that Rexatilux is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Rexatilux is Lucentis. For more information on biosimilar medicines, see here.
Rexatilux is given by intravitreal injection (injection into the vitreous humour, the jelly-like fluid in the eye). It can only be obtained with a prescription and must be given by a qualified eye doctor who is experienced in giving intravitreal injections.
Treatment with Rexatilux is started with one injection every month, with regular checks of the patient’s vision and examination of the back of the eye, until maximum vision is achieved and/or there are no signs of disease activity. The interval between two injections of Rexatilux into the same eye must be at least four weeks. Treatment with Rexatilux should be stopped if the patient is not benefiting from it.
For more information about using Rexatilux, see the package leaflet or contact your doctor or pharmacist.
The active substance in Rexatilux, ranibizumab, is a small piece of a monoclonal antibody. A monoclonal antibody is a type of protein that has been designed to recognise and attach to a specific target (called an antigen) that is found in certain cells in the body.
Ranibizumab has been designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, ranibizumab reduces the growth of the blood vessels and controls the leakage and swelling.
Laboratory studies comparing Rexatilux with Lucentis have shown that the active substance in Rexatilux is highly similar to that in Lucentis in terms of structure, purity and biological activity. Studies have also shown that giving Rexatilux produces similar levels of the active substance in the body to giving Lucentis.
In addition, a study involving 546 people with the wet form of age-related macular degeneration found that Rexatilux produced improvements in the condition comparable to those seen with Lucentis. In this study, the average number of letters patients could recognise on a standard eye test improved by 7 with Rexatilux and by around 8 with Lucentis after 8 weeks of treatment.
Because Rexatilux is a biosimilar medicine, the studies on effectiveness and safety of ranibizumab carried out with Lucentis do not all need to be repeated for Rexatilux.
The safety of Rexatilux has been evaluated and, on the basis of all the studies carried out, the side effects of the medicine are considered to be comparable to those of the reference medicine Lucentis.
For the complete list of side effects and restrictions of Rexatilux, see the package leaflet.
The most common side effects with ranibizumab (which may affect more than 1 in 10 people) include increased intraocular pressure (pressure within the eye), headache, vitritis (inflammation in the eye), vitreous detachment (separation of the vitreous from the back of the eye), retinal haemorrhage (bleeding at the back of the eye), visual disturbance, eye pain, vitreous floaters (spots in the vision), conjunctival haemorrhage (bleeding at the front of the eye), eye irritation, sensation of a foreign body in the eye, increased lacrimation (watery eyes), blepharitis (inflammation of the eyelids), dry eye, ocular hyperaemia (increased blood supply to the eye, leading to redness of the eye), eye pruritus (itching), arthralgia (joint pain) and nasopharyngitis (inflammation of the nose and throat). Rarely, endophthalmitis (an infection inside the eye), blindness, serious damage to the retina and cataract (clouding of the lens) can occur.
Rexatilux must not be used in patients who may have an infection of the eye or of the area around the eye, or who have severe inflammation within the eye.
The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Rexatilux has a highly similar structure, purity and biological activity to Lucentis and is distributed in the body in the same way. In addition, studies in the wet form of age-related macular degeneration have shown that Rexatilux and Lucentis are equivalent in terms of safety and effectiveness in this use.
All these data were considered sufficient to conclude that Rexatilux will have the same effects as Lucentis in its authorised uses. Therefore, the Agency’s view was that, as for Lucentis, the benefits of Rexatilux outweigh the identified risks and it can be authorised for use in the EU.
The company that markets Rexatilux will provide information packs to patients to help them prepare for treatment, recognise serious side effects and know when to seek urgent medical attention.
These materials may be made available by national competent authorities on their websites. A list of national repositories is available on the EMA website.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rexatilux have also been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Rexatilux are continuously monitored. Suspected side effects reported with Rexatilux are carefully evaluated and any necessary action taken to protect patients.
Rexatilux received a marketing authorisation valid throughout the EU on 19 June 2026.
Product information
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Rexatilux
- Active substance
- ranibizumab
- International non-proprietary name (INN) or common name
- ranibizumab
- Therapeutic area (MeSH)
- Wet Macular Degeneration
- Anatomical therapeutic chemical (ATC) code
- S01LA04
Pharmacotherapeutic group
OphthalmologicalsTherapeutic indication
Rexatilux is indicated in adults for:
- The treatment of neovascular (wet) age-related macular degeneration (AMD)
- The treatment of visual impairment due to diabetic macular oedema (DME)
- The treatment of proliferative diabetic retinopathy (PDR)
- The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
- The treatment of visual impairment due to choroidal neovascularisation (CNV).
Assessment history
News on Rexatilux
This page was last updated on